Qiagen NV (QGEN) - Net Assets

Latest as of March 2026: $3.33 Billion USD

Based on the latest financial reports, Qiagen NV (QGEN) has net assets worth $3.33 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.78 Billion) and total liabilities ($2.45 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check QGEN intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $3.33 Billion
% of Total Assets 57.62%
Annual Growth Rate 21.07%
5-Year Change 22.01%
10-Year Change 44.92%
Growth Volatility 57.1

Qiagen NV - Net Assets Trend (1995–2025)

This chart illustrates how Qiagen NV's net assets have evolved over time, based on quarterly financial data. See Qiagen NV (QGEN) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Qiagen NV (1995–2025)

The table below shows the annual net assets of Qiagen NV from 1995 to 2025. For live valuation and market cap data, see Qiagen NV (QGEN) market capitalisation.

Year Net Assets Change
2025-12-31 $3.78 Billion +5.91%
2024-12-31 $3.57 Billion -6.31%
2023-12-31 $3.81 Billion +9.84%
2022-12-31 $3.47 Billion +11.95%
2021-12-31 $3.10 Billion +10.68%
2020-12-31 $2.80 Billion +10.30%
2019-12-31 $2.54 Billion -3.73%
2018-12-31 $2.63 Billion +3.70%
2017-12-31 $2.54 Billion -2.54%
2016-12-31 $2.61 Billion +1.76%
2015-12-31 $2.56 Billion -3.61%
2014-12-31 $2.66 Billion -2.42%
2013-12-31 $2.72 Billion -0.02%
2012-12-31 $2.72 Billion +6.51%
2011-12-31 $2.56 Billion +3.29%
2010-12-31 $2.48 Billion +8.08%
2009-12-31 $2.29 Billion +57.59%
2008-12-31 $1.45 Billion +4.43%
2007-12-31 $1.39 Billion +145.89%
2006-12-31 $566.16 Million +25.69%
2005-12-31 $450.46 Million +12.51%
2004-12-31 $400.38 Million +19.59%
2003-12-31 $334.79 Million +27.28%
2002-12-31 $263.03 Million +23.50%
2001-12-31 $212.97 Million +29.41%
2000-12-31 $164.58 Million +77.61%
1999-12-31 $92.66 Million +26.76%
1998-12-31 $73.10 Million +35.37%
1997-12-31 $54.00 Million +13.21%
1996-12-31 $47.70 Million +290.98%
1995-12-31 $12.20 Million --

Equity Component Analysis

This analysis shows how different components contribute to Qiagen NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 109835.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings $2.75 Billion 72.74%
Common Stock $2.53 Million 0.07%
Other Comprehensive Income $-377.31 Million -9.99%
Other Components $1.40 Billion 37.18%
Total Equity $3.78 Billion 100.00%

Qiagen NV Competitors by Market Cap

The table below lists competitors of Qiagen NV ranked by their market capitalization.

Company Market Cap
Jiangsu Leadmicro Nano Technology Co. Ltd. A
SHG:688147
 $7.62 Billion
Inpost SA
AS:INPST
 $7.62 Billion
Canadian Utilities Limited
TO:CU
 $7.63 Billion
SpareBank 1 Sør-Norge ASA
OL:SB1NO
 $7.63 Billion
Red Electrica Corporacion SA
F:RE2
 $7.62 Billion
South Bow Corporation
TO:SOBO
 $7.61 Billion
The Gap, Inc.
NYSE:GAP
 $7.61 Billion
Shandong Nanshan Aluminium Co Ltd
SHG:600219
 $7.61 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Qiagen NV's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,567,339,000 to 3,778,154,000, a change of 210,815,000 (5.9%).
  • Net income of 424,880,000 contributed positively to equity growth.
  • Dividend payments of 54,244,000 reduced retained earnings.
  • Share repurchases of 307,356,000 reduced equity.
  • Other comprehensive income increased equity by 97,230,000.
  • Other factors increased equity by 50,305,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $424.88 Million +11.25%
Dividends Paid $54.24 Million -1.44%
Share Repurchases $307.36 Million -8.14%
Other Comprehensive Income $97.23 Million +2.57%
Other Changes $50.30 Million +1.33%
Total Change $- 5.91%

Book Value vs Market Value Analysis

This analysis compares Qiagen NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.03x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 233.32x to 2.03x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 $0.16 $36.95 x
1996-12-31 $0.47 $36.95 x
1997-12-31 $0.45 $36.95 x
1998-12-31 $0.52 $36.95 x
1999-12-31 $0.69 $36.95 x
2000-12-31 $1.18 $36.95 x
2001-12-31 $1.52 $36.95 x
2002-12-31 $1.87 $36.95 x
2003-12-31 $2.36 $36.95 x
2004-12-31 $2.80 $36.95 x
2005-12-31 $3.11 $36.95 x
2006-12-31 $3.83 $36.95 x
2007-12-31 $8.21 $36.95 x
2008-12-31 $7.39 $36.95 x
2009-12-31 $11.14 $36.95 x
2010-12-31 $10.69 $36.95 x
2011-12-31 $11.07 $36.95 x
2012-12-31 $11.71 $36.95 x
2013-12-31 $11.64 $36.95 x
2014-12-31 $11.11 $36.95 x
2015-12-31 $11.21 $36.95 x
2016-12-31 $11.33 $36.95 x
2017-12-31 $10.91 $36.95 x
2018-12-31 $11.29 $36.95 x
2019-12-31 $11.53 $36.95 x
2020-12-31 $12.32 $36.95 x
2021-12-31 $13.76 $36.95 x
2022-12-31 $15.53 $36.95 x
2023-12-31 $17.51 $36.95 x
2024-12-31 $16.33 $36.95 x
2025-12-31 $18.17 $36.95 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Qiagen NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.25%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 20.33%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 1.67x
  • Recent ROE (11.25%) is above the historical average (9.22%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 19.67% 6.49% 1.41x 2.15x $1.18 Million
1996 11.11% 9.78% 0.82x 1.39x $530.00K
1997 16.30% 11.84% 0.94x 1.46x $3.40 Million
1998 18.04% 11.95% 1.03x 1.46x $5.87 Million
1999 15.03% 9.65% 0.97x 1.60x $4.65 Million
2000 12.78% 10.29% 0.89x 1.40x $4.56 Million
2001 16.16% 13.05% 0.74x 1.68x $13.12 Million
2002 8.80% 7.75% 0.66x 1.73x $-3.16 Million
2003 12.80% 12.19% 0.64x 1.65x $9.37 Million
2004 12.16% 12.80% 0.53x 1.78x $8.67 Million
2005 13.81% 15.62% 0.52x 1.70x $17.18 Million
2006 12.46% 15.14% 0.38x 2.14x $13.92 Million
2007 3.60% 7.71% 0.23x 1.99x $-89.04 Million
2008 6.12% 9.97% 0.31x 1.98x $-56.35 Million
2009 6.01% 13.64% 0.27x 1.66x $-91.35 Million
2010 5.83% 13.27% 0.28x 1.58x $-103.32 Million
2011 3.77% 8.21% 0.31x 1.47x $-158.79 Million
2012 4.77% 10.32% 0.30x 1.52x $-141.96 Million
2013 2.54% 5.31% 0.32x 1.51x $-202.36 Million
2014 4.50% 8.65% 0.30x 1.72x $-142.07 Million
2015 5.08% 10.16% 0.31x 1.64x $-125.84 Million
2016 3.08% 6.01% 0.31x 1.65x $-180.31 Million
2017 1.59% 2.85% 0.28x 1.98x $-213.71 Million
2018 7.23% 12.68% 0.26x 2.18x $-73.12 Million
2019 -1.63% -2.72% 0.29x 2.06x $-295.11 Million
2020 12.84% 19.20% 0.32x 2.10x $79.40 Million
2021 16.55% 22.77% 0.37x 1.99x $202.94 Million
2022 12.21% 19.76% 0.34x 1.81x $76.55 Million
2023 8.96% 17.37% 0.32x 1.61x $-39.47 Million
2024 2.34% 4.23% 0.35x 1.59x $-273.14 Million
2025 11.25% 20.33% 0.33x 1.67x $47.06 Million

Industry Comparison

This section compares Qiagen NV's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $836,732,192
  • Average return on equity (ROE) among peers: -59.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Qiagen NV (QGEN) $3.33 Billion 19.67% 0.74x $7.62 Billion
Agilent Technologies Inc (A) $5.84 Billion 21.21% 0.84x $35.96 Billion
Advanced Biomed Inc. Common Stock (ADVB) $1.66 Million -167.28% 1.68x $6.13 Million
Applied DNA Sciences Inc (APDN) $-1.47 Million 0.00% 0.00x $3.99 Million
Biodesix Inc (BDSX) $41.17 Million -76.16% 1.94x $79.44 Million
bioAffinity Technologies, Inc. (BIAF) $-15.07 Million 0.00% 0.00x $3.77 Million
Biocept Inc. (BIOCQ) $37.48 Million -7.53% 0.61x $525.00
BillionToOne, Inc. Class A Common Stock (BLLN) $30.47 Million -271.32% 5.29x $4.36 Billion
Burning Rock Biotech Ltd (BNR) $2.42 Billion -16.82% 0.10x $63.90 Million
CareDx Inc (CDNA) $-5.95 Million 0.00% 0.00x $1.13 Billion
Check Cap Ltd (CHEK) $13.03 Million -81.27% 0.18x $9.42 Million

About Qiagen NV

NYSE:QGEN USA Diagnostics & Research
Market Cap
$7.62 Billion
Market Cap Rank
#2757 Global
#975 in USA
Share Price
$36.95
Change (1 day)
+1.01%
52-Week Range
$32.63 - $55.66
All Time High
$56.87
Categories
Companies in USA Diagnostics & Research
About

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more